Cosmo stock
CMHC.SWSIXCosmo N.V., HealthcareISIN NL0011832936
37Score 37 out of 100, Weak
Price and trend
51 / 100
Price history
−11% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 21% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 53% below its 52-week high. Largest decline in 20 years: 82% (July 2014 to October 2023).
Chart figures for advanced users
- SMA 50$65.44
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$88.83
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$58.81
- The lowest closing price of the last twelve months.
- Resistance$149.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Cosmo N.V. belongs to the Medical (Pharmaceuticals) industry (Ireland) and, with a market value of $1.21B, is number 15 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $116.19M (down 60.7% year on year) and a loss of $4.02M.
- MEQIRI Score 37 out of 100 (Weak): rank 593 of 716 in Healthcare, median 53.
Show more
- Our model puts fair value at $51.89, with the price 33% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $216.39M, financial debt $4.8M.Stability 61
- High dividend yieldDividend yield 3.4%, Healthcare sector median 1.37%.
Weaknesses
- Margin fallingOperating margin −10%, average of the prior years 17.1% (to 2024).Profitability 22
- Loss-makingLoss of $7.03M over the last 12 months.Fundamentals 23
- Negative free cash flowFree cash flow −$26.39M over the last 12 months.Fundamentals 23
The score is held back by profitability and capital allocation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- high price swings
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $37.06 and expensive above $86.48 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 7.5%. At 8.5% the fair value would be $42.43, at 6.5% it would be $66.13.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 43.7% on the twelve months before. Revenue has grown solidly since 2006, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 47%, operating −10%, net −3%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Mar 2027in 131 days
- Last reported
- 23 Jul 2026EPS reported −0.26 (expected −0.03)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 0.14−1.8%
- Revenue
- $116.91M−1.8%
- Earnings per share
- 0.61−1.8%
- Revenue
- $140.72M−1.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Cosmo
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
716 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Tsuruha Holdings3391.T $7.1B62
- MatsukiyoCocokara3088.T $6.71B75
- Abbott IndiaABBOTINDIA.NS $6.01B75
- LiquidiaLQDA $5.24B43
- Beijing Tongrentang600085.SS $5B57
- Prestige Consumer HealthcarePBH $2.09B54
- Achieve Life SciencesQUIT $663.72M41
- SwedencareSECARE.ST $310.94M52
ETFs that hold Cosmo
Held by 5 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.07% | 0.23% | €319.31M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Show 1 more
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.